These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22897163)

  • 1. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
    Lyseng-Williamson KA
    Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
    Croxtall JD
    Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
    Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
    Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
    Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
    Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine(Intelence) for HIV infection.
    Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
    Floris-Moore MA; Mollan K; Wilkin AM; Johnson MA; Kashuba AD; Wohl DA; Patterson KB; Francis O; Kronk C; Eron JJ
    Antivir Ther; 2016; 21(1):55-64. PubMed ID: 26263403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
    Messou E; Chaix ML; Gabillard D; Yapo V; Toni TD; Minga A; Kouakou MG; Ouattara E; Rouzioux C; Danel C; Eholie SP; Anglaret X
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):211-9. PubMed ID: 23797690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
    ; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
    AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
    DeJesus E; Fätkenheuer G; Orrell C; Wang C; Jones J; Craig C; Tawadrous M; Heera J
    HIV Clin Trials; 2014; 15(5):209-17. PubMed ID: 25350959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
    Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
    Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
    Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
    HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine: R165335, TMC 125, TMC-125, TMC125.
    Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
    J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.